Table 2

Characteristics of the current study population
Characteristic Men Women
n = 24,389 (41.0%) n = 35,078 (59.0%)
BMI <25 BMI 25 to 30 BMI ≥30 Pvalue BMI <25 BMI 25 to 30 BMI ≥30 Pvalue
n (%) 9,112 (37.4%) 11,763 (48.2%) 3,514 (14.4%) 17,750 (50.6%) 11,667 (33.3%) 5,661 (16.1%)
Age, years 42 ± 12 47 ± 11 48 ± 11 <0.001 42 ± 12 47 ± 12 47 ± 12 <0.001
BMI, kg/m2 23.0 ± 1.5 27.1 ± 1.4 32.8 ± 2.9 <0.001 22.4 ± 1.7 27.1 ± 1.4 34.1 ± 3.9 <0.001
Smoking status
Non-smoker, n (%) 4,467 (49.0%) 4,751 (40.4%) 1,311 (37.3%) 8,753 (49.3%) 5,080 (43.5%) 2,623 (46.3%)
Former smoker, n (%) 2,401 (26.3%) 4,384 (37.3%) 1,390 (39.6%) 5,248 (29.6%) 4,298 (36.8%) 2,087 (36.9%)
Current smoker, n (%) 2,244 (24.6%) 2,628 (22.3%) 813 (23.1%) 3,749 (21.1%) 2,289 (19.6%) 951 (16.8%)
SBP, mmHg 127 ± 12 133 ± 13 137 ± 14 <0.001 119 ± 14 125 ± 15 130 ± 15 <0.001
DBP, mmHg 74 ± 8 78 ± 9 80 ± 9 <0.001 70 ± 8 73 ± 9 75 ± 9 <0.001
Total cholesterol, mmol/l 4.9 ± 1.0 5.2 ± 1.0 5.2 ± 1.0 <0.001 4.9 ± 1.0 5.1 ± 1.0 5.1 ± 1.0 <0.001
LDL-C, mmol/l 3.17 ± 0.86 3.47 ± 0.87 3.44 ± 0.91 <0.001 2.91 ± 0.84 3.25 ± 0.90 3.26 ± 0.88 <0.001
HDL-C, mmol/l 1.40 ± 0.32 1.25 ± 0.29 1.12 ± 0.26 <0.001 1.69 ± 0.39 1.54 ± 0.36 1.38 ± 0.33 <0.001
Triglycerides, mmol/la 0.98 (0.71 to 1.31) 1.31 (0.91 to 1.80) 1.62 (1.15 to 2.23) <0.001 0.81 (0.61 to 1.04) 0.99 (0.72 to 1.33) 1.20 (0.86 to 1.61) <0.001
Apolipoprotein A1, g/lb 1.47 ± 0.23 1.41 ± 0.21 1.36 ± 0.21 <0.001 1.66 ± 0.28 1.60 ± 0.26 1.52 ± 0.26 <0.001
HDL-C/apoA1 ratiob 0.93 ± 0.13 0.86 ± 0.12 0.81 ± 0.11 <0.001 1.00 ± 0.14 0.95 ± 0.50 0.90 ± 0.49 <0.001
Apolipoprotein B, g/lb 0.91 ± 0.23 1.01 ± 0.24 1.05 ± 0.24 <0.001 0.84 ± 0.22 0.94 ± 0.24 0.97 ± 0.24 <0.001
LDL-C/apoB ratiob 3.51 ± 0.35 3.44 ± 0.40 3.32 ± 0.42 <0.001 3.45 ± 0.36 3.46 ± 0.36 3.37 ± 0.38 <0.001
Blood glucose, mmol/la 4.94 (4.60 to 5.20) 5.18 (4.80 to 5.40) 5.52 (5.00 to 5.80) <0.001 4.70 (4.40 to 4.90) 4.94 (4.60 to 5.20) 5.26 (4.80 to 5.50) <0.001
Waist circumference, cm 87 ± 6 98 ± 6 112 ± 9 <0.001 79 ± 7 90 ± 7 105 ± 10 <0.001
BP-lowering medication, n (%) 462 (5.1%) 1,516 (12.9%) 843 (24.0%) <0.001 1,050 (5.9%) 1,563 (13.4%) 1,351 (23.9%) <0.001
Statin use, n (%) 267 (2.9%) 1,008 (8.6%) 473 (13.5%) <0.001 364 (2.1%) 608 (5.2%) 457 (8.1%) <0.001
TG-lowering medication, n (%) 6 (0.1%) 32 (0.3%) 13 (0.4%) <0.001 3 (0.0%) 11 (0.1%) 8 (0.1%) 0.0012
Type 2 diabetes, n (%) 53 (0.6%) 203 (1.7%) 204 (5.8%) <0.001 55 (0.3%) 150 (1.3%) 267 (4.7%) <0.001
Oral antihyperglycemic medication, n (%) 38 (0.4%) 175 (1.5%) 175 (5.0%) <0.001 44 (0.2%) 118 (1.0%) 211 (3.7%) <0.001
Percentage fulfilling ≥3 out of 5 metabolic syndrome criteriac 330 (3.6%) 2,544 (21.6%) 2,259 (64.3%) <0.001 425 (2.4%) 1,871 (16.0%) 2,351 (41.5%) <0.001

Data are presented as mean ± SD, or median (interquartile range).

aData given as geometric mean (interquartile range).

bApoA1 and apoB results (and their ratios) were available in 34,613 and 34,601 of the 59,467 subjects, respectively.

cFor subjects with BMI ≥30 kg/m2, two out of four criteria.

Apo apolipoprotein, BMI body mass index, BP blood pressure, DBP diastolic blood pressure, HDL-C high-density lipoprotein-cholesterol, LDL-C low-density lipoprotein-cholesterol, SBP systolic blood pressure, TG triglycerides.

Slagter et al.

Slagter et al. BMC Medicine 2013 11:195   doi:10.1186/1741-7015-11-195

Open Data